Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 12/20 | 0.58 |
| ▸ | MAOB | P27338 | 12/20 | 0.58 |
| ▸ | MAOA | P21397 | 9/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3349212 | 0.89 | KDM1A (0.64) | KDM1AMAOBMAOALMNASMN1; SMN2 | |
| SCHEMBL3349219 | 0.89 | KDM1A (0.64) | KDM1AMAOBMAOALMNASMN1; SMN2 | |
| SCHEMBL2549491 | 0.87 | KDM1A (0.53) | KDM1AMAOBMAOA | |
| SCHEMBL19609403 | 0.78 | KDM1A (0.42) | KDM1AMAOBMAOA | |
| SCHEMBL13277597 | 0.76 | MAOB (0.48) | KDM1AMAOBRAB9A | |
| SCHEMBL13277598 | 0.76 | MAOB (0.48) | KDM1AMAOBRAB9A | |
| SCHEMBL19609354 | 0.74 | KDM1A (0.46) | KDM1AMAOBMAOAL3MBTL1 | |
| SCHEMBL19585902 | 0.74 | KDM1A (0.48) | KDM1AMAOBMAOALMNAPOLB | |
| SCHEMBL1670147 | 0.74 | KCNH2 (0.46) | KDM1AMAOBRAB9A | |
| SCHEMBL1670144 | 0.74 | KCNH2 (0.46) | KDM1AMAOBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524717-B2 | Oxidase inhibitors and their use | ORYZON GENOMICS, S.A. (ES) | 2013-09-03 | — | — | US | disclosed |
| US-20110263604-A1 | Oxidase inhibitors and their use | ORYZON GENOMICS, S.A. (ES) | 2011-10-27 | — | — | US | disclosed |
| EP-2361242-A1 | OXIDASE INHIBITORS AND THEIR USE | Oryzon Genomics, S.A. (ES) | 2011-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263604-A1 | Oxidase inhibitors and their use | MAOA, PNPO, MAOB | KDM1A 920/4885MAOB 3/4885MAOA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.